Sutimlimab Suppressed CAD Response in Heart Surgery Patient

Sutimlimab Suppressed CAD Response in Heart Surgery Patient

312456

Sutimlimab Suppressed CAD Response in Heart Surgery Patient

Suppressing the pro-inflammatory complement pathway using sutimlimab, in addition to other measures, can help prevent red blood cell destruction in patients with cold agglutinin disease (CAD) undergoing major surgery, a recent case report suggests The study, “Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anaemia in a patient with cold agglutinin disease undergoing major surgery,” was published in the American Journal of Hematology. Cold agglutinins are autoantibodies directed against proteins found on the…

You must be logged in to read/download the full post.